TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03436940

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: On Demand Discharge Planning (DDP)
Description: Patients with an intermediate score, according to the simplified Blaylock Risk Assessment Screening Score, are addressed to the NOCC team (hospital Continuity of care team) only in case of a specific request by the unit of hospitalization.
Study: NCT03607916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric prilocaine 2%
Description: Varying dose according to sensitive response of previous subjects. All study doses of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric prilocaine 2%
Description: Varying dose according to sensitive response of previous subjects. All study doses of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric prilocaine 2%
Description: Varying dose according to sensitive response of previous subjects. All study doses of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric prilocaine 2%
Description: Varying dose according to sensitive response of previous subjects. All study doses of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric prilocaine 2%
Description: Varying dose according to sensitive response of previous subjects. All study doses of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric prilocaine 2%
Description: The dose of 60 mg of Hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 100µg morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 100µg morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 100µg morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 100µg morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 100µg morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 100µg morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 100µg morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 100µg morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 100µg morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 100µg morphine
Study: NCT00864162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril10 mg Capsules, single dose
Description: A: Experimental Subjects received Purepac formulated products under fed conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atlace® 10 mg capsules, single dose
Description: B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products under fed conditions
Study: NCT00859170

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accordion device
Description: an antiretropulsion device
Study: NCT00523185

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: Lorazepam 1 to 2 mg by mouth or intravenously every two hours as needed for alcohol withdrawal symptoms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam
Description: Diazepam 20 mg by mouth every two hours x 3 doses, or for parenteral treatment, diazepam 10 mg intravenously every one hour x 6 doses. Give additional diazepam 10 mg by mouth or intravenously every two hours as needed for alcohol withdrawal symptoms.
Study: NCT04399161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Description: A commercially available Chlorhexidine mouth rinse (Hexidine- 0.2 percentage Chlorhexidine gluconate) containing 0.2 percentage chlorhexidine gluconate per 10 ml will be used. 7.5 ml of the concentrate diluted with equal amounts of water to make 15ml will be used for rinsing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Description: A commercially available Chlorhexidine mouth rinse (Hexidine- 0.2 percentage Chlorhexidine gluconate) containing 0.2 percentage chlorhexidine gluconate per 10 ml will be used. 7.5 ml of the concentrate diluted with equal amounts of water to make 15ml will be used for rinsing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylitol
Description: Xylitol mouth rinse at 10 percentage concentration will be used. The mouth rinse will be prepared by dissolving 1.5 gm of xylitol powder in 15 ml of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylitol
Description: Xylitol mouth rinse at 10 percentage concentration will be used. The mouth rinse will be prepared by dissolving 1.5 gm of xylitol powder in 15 ml of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotic mouth rinse will be prepared by using a commercially available probiotic product (Sporolac Plus powder- 1gm sachet containing not less than 1.5 billion cells of Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium longum, Bacillus coagulans, Saccharomyces boulardii). Each sachet will be dissolved in 15 ml of water in a measuring cup and used as a mouth rinse.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotic mouth rinse will be prepared by using a commercially available probiotic product (Sporolac Plus powder- 1gm sachet containing not less than 1.5 billion cells of Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium longum, Bacillus coagulans, Saccharomyces boulardii). Each sachet will be dissolved in 15 ml of water in a measuring cup and used as a mouth rinse.
Study: NCT02761811

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator
Description: Radiofrequency ablation of renal arterial sympathetic nerves

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator
Description: Radiofrequency ablation of renal arterial sympathetic nerves
Study: NCT03702478

Intervention type: OTHER
Intervention: Questionnaire
Description: No intervention only observational
Study: NCT01466270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study: NCT03984695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHE-WOMEN
Description: SHE-WOMEN is a text-Web intervention designed to increase jail-involved women's health literacy, reduce risk, and increase screening for prevention of cervical cancer, breast cancer, unintended pregnancy, and sexually transmitted infections.
Study: NCT03901924

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Volume Support Mode Mechanical Ventilation
Description: This is a spontaneous mode of mechanical ventilation that depends on the patient's efforts. A target volume (6 cc/kg of IBW), PEEP and FiO2 are set by the medical team, and the ventilator varies the inspiratory pressure support with each breath to achieve the target volume. The respiratory rate is fully dependent on the patient. Sedation while on mechanical ventilation will be set at a goal RASS of 0 to -2.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assist Control Mode Mechanical Ventilation
Description: This is a controlled mode of mechanical ventilation that is independent of patient's efforts. A tidal volume (6 cc/kg of IBW), respiratory rate, PEEP and FiO2 are set by the medical team. Sedation while on mechanical ventilation will be set at a goal RASS of 0 to -2.
Study: NCT00424905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacillus clausii
Description: 2 Enterogermina vials/day for 12 to 17 days (i.e. during the 5 to 10-days antibiotic treatment and for 7 days thereafter.
Study: NCT03436940

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Discharge Planning (RDP)
Description: All patients with an intermediate threshold value of the simplified Blaylock Risk Assessment Screening Score are submitted to discharge planning by the NOCC team (Hospital Unit of Continuity of Care)
Study: NCT02404675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: icotinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: icotinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: icotinib
Study: NCT01796769

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) in sleep apnea patients
Description: Usual CPAP treatment in sleep apnea patients

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP) in sleep apnea patients
Description: CPAP treatment with telemedicine system
Study: NCT01953523

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Administration of autologous adipose derived SVF
Description: Intra-venous, intra-articular, and soft tissue injection delivery of SVF
Study: NCT03403010

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation-specific gaming platform
Description: The rehabilitation specific gaming software was developed as part of the ICT4rehab project with partners from the Vrije Universiteit Brussel and the University Libre de Bruxelles. The ICT4Rehab puts several ICT tools supporting 2/3D user interaction into place. The games can be controlled using a Kinect camera system (Microsoft(®) (Redmond, WA) Kinect™) or a Wii balance board (® NintendoTM, Japan), depending on the choice of the therapist and the needs of the child.
Study: NCT02724449

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cavilon Advanced Barrier Film
Description: Cavilon Advanced Barrier Fim's application applied twice a week
Study: NCT00664885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Culturally Sensitive Collaborative Treatment
Description: a collaborative care model, for treating depressed patients in general medical care
Study: NCT00587678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 40mg each night

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: 10mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin/Ezetimibe
Description: 40mg/10mg each night
Study: NCT01324661

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Ostracism
Description: Participants would received the ball of a computerized ball-tossing game once or twice in the beginning and then never again for the duration of the game.
Study: NCT00997802

Intervention type: DEVICE
Group type: OTHER
Intervention: CT colonography and optical colonoscopy
Description: All patients will undergo CT colonography and optical colonoscopy.
Study: NCT00652795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline Monohydrate
Description: Tablets, 150 mg, single-dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monodox
Description: Capsules 50 mg (3 x 50 mg dose), single-dose
Study: NCT03501225

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ozone
Description: After local anesthesia, it was performed sulcular incision with scalpel blade number 15 and removal of soft tissues. Osteotomy was performed at low rotation and odontosecion at high speed, under constant irrigation with ozonated water. Tooth removal, careful curettage, bone regularization and surgical shop cleaning were then performed under abundant irrigation with ozonated water according to randomization. The suture was then performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: water
Description: After local anesthesia, it was performed sulcular incision with scalpel blade number 15 and removal of soft tissues. Osteotomy was performed at low rotation and odontosecion at high speed, under constant irrigation with redistilled water. Tooth removal, careful curettage, bone regularization and surgical shop cleaning were then performed under abundant irrigation with redistilled water according to randomization. The suture was then performed.
Study: NCT04236674

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy thermomechanical device
Description: Buzzy thermomechanical device placed near intervention site.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy thermomechanical device
Description: Buzzy thermomechanical device placed near intervention site.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Selection
Description: Patient specified procedural music

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Selection
Description: Patient specified procedural music
Study: NCT02238119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium + formoterol combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Study: NCT00920855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine
Description: Bendamustine was administered to 3 cohorts of patients at escalating doses of 50 (cohort 1), 70 (cohort 2) and 90 mg/m\^2/dose (cohort 3). Doses were administered by intravenous (iv) infusion once daily on days 1 and 4 of each 28-day cycle. Each iv was administered over 60 minutes and followed the injection of bortezomib.~Bortezomib will be administered to patients at a dose of 1.0 mg/m2/dose as an iv push over 3 to 5 seconds followed by a standard saline flush or through a running iv line. Doses are to be administered to patients on days 1, 4, 8 and 11 of the 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Bortezomib was administered at a dose of 1.0 mg/m\^2/dose as an intravenous (iv) push over 3 to 5 seconds followed by a standard saline flush or through a running iv line. Doses are to be administered on days 1, 4, 8 and 11 of each 28-day cycle.
Study: NCT00356681

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMG 706 placebo
Description: Blinded placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab is a recombinant, humanized anti-VEGF monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 706
Description: AMG 706 is a small organic molecule that has been shown in preclinical pharmacology and PK studies to be a potent, oral, multi-kinase inhibitor with anti-angiogenic and anti-tumor activity achieved by selectively targeting all known VEGF, PDGF and Kit receptors.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel is an antineoplastic agent that acts by promoting and stabilizing the polymerization of microtubules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is an antineoplastic agent that acts by promoting and stabilizing the polymerization of microtubules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel is an antineoplastic agent that acts by promoting and stabilizing the polymerization of microtubules.
Study: NCT04163575

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: :Anti-CD22-CAR
Description: Cells extracted, followed by induction chemotherapy before CD22-CAR infusion (dose escalation.)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: :Anti-CD22-CAR
Description: Cells extracted, followed by induction chemotherapy before CD22-CAR infusion (dose escalation.)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: :Anti-CD22-CAR
Description: Cells extracted, followed by induction chemotherapy before CD22-CAR infusion (dose escalation.)
Study: NCT05586919

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Puncture Repair / Ethanol
Description: Ethanol is an organic compound that will be injected in the venous malformation as a sclerotherapy by Direct Puncture Repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Puncture Repair / Polidocanol
Description: Polidocanol is a sclerosing agent that will be injected in the venous malformation by Direct Puncture Repair
Study: NCT02347839

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gefitinib-surgery-gefitinib
Description: neoadjuvant gefitinib followed by surgery, followed by adjuvant gefitinib
Study: NCT02489539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE® EXCLUDER® Conformable AAA Endoprosthesis
Description: Endovascular Aneurysm repair (EVAR) is a minimally invasive procedure designed to exclude an aneurysmal segment of the aorta from blood circulation. The EVAR procedure involves delivery of a stent- graft compressed onto a catheter to an aneurysmal segment of the aorta from a remote access site, generally the femoral artery. Arterial access may be done by either percutaneous or cut-down technique.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE® EXCLUDER® Conformable AAA Endoprosthesis
Description: Endovascular Aneurysm repair (EVAR) is a minimally invasive procedure designed to exclude an aneurysmal segment of the aorta from blood circulation. The EVAR procedure involves delivery of a stent- graft compressed onto a catheter to an aneurysmal segment of the aorta from a remote access site, generally the femoral artery. Arterial access may be done by either percutaneous or cut-down technique.
Study: NCT00881114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intensity modulated radiation therapy with concurrent chemotherapy. Cisplatin will be administered at a dose of 100 mg/m2 during weeks 1, 4, and 7 of radiation therapy. Post treatment neck dissection will be performed if clinically indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Intensity modulated Radiation Therapy with concurrent chemotherapy. Cetuximab will be administered beginning at a dose of 400 mg/m2 the week before radiation commences, then at a dose of 250 mg/m2 weekly during weeks 1 to 7. Post treatment neck dissection will be performed if clinically indicated.
Study: NCT05187078

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allis clamp
Description: Physicians utilized an Allis clam for cervical stabilization during IUD placement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-tooth tenaculum
Description: Physicians utilized a single-tooth tenaculum clam for cervical stabilization during IUD placement.
Study: NCT03342417

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg administered by IV infusion over 30 minutes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg administered by IV infusion over 30 minutes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg administered by IV infusion over 30 minutes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 1 mg/kg administered by IV infusion over 30 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 1 mg/kg administered by IV infusion over 30 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 1 mg/kg administered by IV infusion over 30 minutes.
Study: NCT02936674

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light - standard
Description: Light will be given during the night to determine its effects on melatonin suppression. This light will be an LED with standard spectral distribution

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light - alternate
Description: Light will be given during the night to determine its effects on melatonin suppression. This light will be an LED with an altered spectral distribution (different color)
Study: NCT04017065

Intervention type: DEVICE
Intervention: DePuy Synthes MAXFRAMETM system
Description: Patients treated with the MAXFRAMETM system will be followed up from before the surgery until the removal of the device. All treatments are based on individual clinician's judgement and the patient characteristics. The registry does not dictate any specific treatment.
Study: NCT01330407

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cryopreserved skin allografts.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cultured Epidermal Autografts
Study: NCT02594254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16G2 Gel
Description: Antimicrobial peptide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16G2 Gel
Description: Antimicrobial peptide
Study: NCT02025179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Teriparatide 20 ug daily Sub-Q over 12 months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration
Description: Vibration 10 min/day for 12 months
Study: NCT02435004

Intervention type: DEVICE
Group type: OTHER
Intervention: Spinal Modulation Axium™
Description: The participants will undergo implantation of electrodes for stimulation of fuor dorsal ganglia (Spinal Modulation, Inc., Menlo Park, CA, USA). Each participant will have one to four electrodes positioned according to the individual distribution of pain in the extremities. After implantation the electrode will be connected to an external neurostimulator: Spinal Modulation Axium™ for 3-30 days to evaluate their effectiveness (test stimulation).~If during the trial treatment the pain will decrease significantly (\> 50%) a neurostimulator will be 'implanted for the continuation of the permanent neurostimulation. The neurostimulator is implanted in the abdomen in a subcutaneous pocket.
Study: NCT03123666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMCSF
Description: GM CSF (Sargamostatim-250mcg/M2) over 4 hour and inhalation of same dose by micronebulizer

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identical to GMCSF will be given
Study: NCT05570266

Intervention type: DIAGNOSTIC_TEST
Intervention: Breast Cancer Risk Prediction Software
Description: Genotyping of known breast cancer-related markers (313 variants) will be conducted using a microarray genotyping chip (Genetic Risk). Survey answers will determine Gail Model scores and thus Clinical Risk Score.
Study: NCT02594254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16G2 Gel
Description: Antimicrobial peptide